We are so grateful to new FDA Commissioner @FDA_KyleD and the entire agency for their commitment to regulatory flexibility and progress. It was an honor to be in the room with other rare disease leaders to recommend concrete changes and advance therapies.
Lou Gehrig's story is part of our history.
People living with ALS are fighting for their future.
Scientific progress is advancing rapidly. People living with ALS deserve every opportunity to benefit from it. @RCJAPH
https://t.co/Uhe0cZqKkA
#LouGehrigDay#StrikeOutALS
We have exciting news! Thanks to our generous sponsors, virtual registration for #ALSNexus is now FREE for people living with ALS and their caregivers! We're grateful for the support that makes this possible and hope you’ll join us. Register today to attend ALS Nexus: https://t.co/QMwyzINYUJ
A Citizen Petition was submitted to the FDA requesting a new review of data supporting NurOwn®.
We remain focused on advancing the ENDURANCE Phase 3b trial and exploring pathways that could bring meaningful options to people living with #ALS.
Here: https://t.co/ObN1fVHbEF
Have you registered for the 2025 NEALS Annual Meeting? 🧠
📅 October 7–10 2025 📍 Clearwater, FL
Join us in person or virtually for four days of collaboration, science, and community in ALS research.
🔗 Learn more & register today: https://t.co/RZLJZ06YeW
I’m excited to speak again tomorrow on the National Mall at the @iamalsorg ALS Community Summit in front of 6,000 blue flags, including one with my mother’s name on it. #EndALS#ALSisHere#SoAreWe
🗓️🌟May is ALS Awareness Month!
Join us as we highlight the latest in ALS research, honor those affected, and work together to accelerate treatments. Follow along and help spread awareness. #ALSawarenessMonth#NEALSforALS#ALSawarenessMonth#NEALSforALS
Reposting with immense pride! The "Breakthrough Science" recognition for our NurOwn® data at #ISCT2025, especially the #UNC13A findings in #ALS, fuels our drive as we move towards our pivotal Phase 3b trial.This validates the potential of our MSC-NTF cell therapy to change lives.
Exciting news! Our NurOwn® data has been selected as "Breakthrough Science" for #ISCT2025, emphasizing the role of the #UNC13A genotype in ALS treatment response. A significant stride in neurodegenerative disease research. Read the full press release here: https://t.co/mV6AvhVwoP
#ALS #NeurodegenerativeDiseases #MSCCellTherapy #ISCT2025 #BrainStormCellTherapeutics
As Rare Disease Day approaches, let’s shine a light on the over 300 million people worldwide living with a rare disease including the 500,000 people globally living with ALS. For those living with ALS and other rare diseases, every day is a fight for time, treatments and hope.